Navigation Links
ARX-01 and ARX-03 Clinical Results Presented at the 30th Annual Scientific Meeting of the American Pain Society
Date:5/18/2011

ia for patients undergoing painful office-based procedures.  Neil Singla, MD of Lotus Clinical Research in Pasadena, CA will present data from 40 patients who underwent elective low-volume liposuction.  Administration of ARX-03 produced mild sedation and anxiolysis with rapid onset of effect, high physician and patient evaluations of effectiveness and tolerability, and a low incidence of side effects.  Copies of these abstracts are available from the AcelRx Pharmaceuticals web site at www.acelrx.com/technology/publications.

About AcelRx Pharmaceuticals, Inc.

Based in Redwood City, CA, AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab(R) PCA System, which has completed Phase 2 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia (IV PCA) which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. AcelRx has two additional product candidates which have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office.

Forward Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to AcelRx Pharmaceuticals' statements related to clinical trial updates, effectiven
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
2. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
3. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 /PRNewswire/ ... VRX ) (TSX: VRX) ... directors nominated at its 2013 annual ... results of the vote for the ... below:  NameForWithheldRonald H. Farmer235,731,9341,964,748Robert A. Ingram233,865,8763,830,806Theo ...
(Date:5/21/2013)... Massachusetts , 21. Mai 2013 /PRNewswire/ ... („OSI"), die die Firmen OMNIlife science® Inc., Enztec ... zählt, hat zwei neue, erfahrene Mitglieder in ... , eine erfahrene Führungspersönlichkeit aus der ... David Johnson , anerkannter ...
(Date:5/21/2013)... , 21 de mayo de 2013 La ... compañías filiales incluyen OMNIlife science®, Inc., Enztec, Ltd. y ... para su junta. Guy Mayer, un ejecutivo ortopédico experimentado, ... David Johnson , un experto refutado ... Antes de unirse a OSI como presidente ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces 2013 Annual Meeting Results 2Orthopaedic Synergy Inc. meldet bedeutenden Zuwachs im Vorstand 2Orthopaedic Synergy Inc. meldet bedeutenden Zuwachs im Vorstand 3Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 3
... improvement solutions provider GP Strategies Corporation (NYSE: ... ended March 31, 2012. Overview of First Quarter ... quarter of 2012 compared to $64.3 million for first quarter of ... of 2012 compared to $4.3 million for first quarter of 2011 ...
... 2012 Valeant Pharmaceuticals International, Inc. (NYSE: ... that Valeant has agreed to acquire certain assets ... company focused on skincare products, for approximately $64 ... future revenue targets.  University Medical,s main brand is ...
Cached Medicine Technology:GP Strategies Reports Strong First Quarter 2012 EPS of $0.23 2GP Strategies Reports Strong First Quarter 2012 EPS of $0.23 3GP Strategies Reports Strong First Quarter 2012 EPS of $0.23 4GP Strategies Reports Strong First Quarter 2012 EPS of $0.23 5GP Strategies Reports Strong First Quarter 2012 EPS of $0.23 6Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical 2
(Date:5/21/2013)... Boca Raton, Fla. (PRWEB) May 21, 2013 ... TV program distributed on cable networks and cable channels ... of new episodes on its YouTube channel. The producers ... profiles of companies in the shipping industry, the manufacturing ... program highlights pioneering medical facilities and medical practitioners in ...
(Date:5/21/2013)... MedMar Healing Center announces their participation in ... Bank. Twenty-eight businesses, including MedMar Healing Center, doctors, and clubs, ... goal is to raise food to help area kids who ... in recent years. , “We like being able to ... explains Douglas Chloupek of MedMar Healing Center. “Taking part in ...
(Date:5/21/2013)... (May 21, 2013) Research into genetic features of ... of Colorado School of Medicine may lead to improved ... paper published online by JAMA . , The ... survival in some cases of pulmonary fibrosis, a chronic ... As a result of the study, researchers may want ...
(Date:5/21/2013)... 2013 The nation’s first trial involving ... nearing its conclusion in Washington state court, Bernstein Liebhard ... yesterday, an attorney for the Plaintiffs compared Intuitive Surgical ... tie sales and services for its customers. ... control of surgeons, to keep control of hospitals and ...
(Date:5/21/2013)... May 21, 2013 Two executives from ... (SBG) will identify which strategies can be most effective ... care to the members who are taking them, in ... Inc., “How to Manage Specialty Drugs to Reduce ... are now the main driver for rising prescription drug ...
Breaking Medicine News(10 mins):Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4Health News:Consulting Firm Execs to Discuss Strategies for Effective Management of Specialty Drugs in AIS’s May 30 Webinar 2
... MONICA, Calif., Dec. 7 California,s,stem cell agency ... it was,rejecting 10 applications for research grants because ... billion stem cell program, the,Foundation for Taxpayer and ... consumer advocacy organization added that,to completely resolve the ...
... Dec. 7 Legendary blues artists Bobby,Rush and James ... the inaugural Mississippi Blues Marathon and Half-Marathon on Saturday,January ... & Mal,s, located at 200,South Commerce Street, in downtown ... scheduled to go on stage at 8:00 p.m., and ...
... for four blood proteins may provide a less-invasive follow-up for ... tomography (CT) scans, according to a new study led by ... a very high false positive rate when trying to discover ... Duke and lead investigator on the study. What that leads ...
... BioHorizons Implant Systems,Inc. relocated its global ... 44,000 square foot facility. The new facility, ... services, a newly,formed manufacturing facility and a ... surface treatment and packaging services., The ...
... 7 As of December 7,2007, Coshocton County Memorial ... nurses for a 3-year contract. As a result,bargaining unit ... strike,and maintain a picket line starting at 7:00 a.m. ... highly developed skills and extensive,education. Each and every day ...
... BAN(R)/Seventeen.com Stress Relief Survey are in, NEW YORK, Dec. ... and messy breakups anymore. The fast-paced world we live in ... people, especially young,women, face. This trend can be seen in ... what are some of the factors that contribute,to this new ...
Cached Medicine News:Health News:Stem Cell Institute Correct in Rejecting Applications Over Conflicts of Interest; Institutions, Board Members Involved Must Be Identified, Consumer Advocates Say 2Health News:Stem Cell Institute Correct in Rejecting Applications Over Conflicts of Interest; Institutions, Board Members Involved Must Be Identified, Consumer Advocates Say 3Health News:Study points to possibility of blood test to detect lung cancer 2Health News:BioHorizons Expands to New 44,000 Square Foot Facility 2Health News:Coshocton County Memorial Hospital RNs to Strike Despite Hospital's Claim of Financial Hardship 2Health News:Coshocton County Memorial Hospital RNs to Strike Despite Hospital's Claim of Financial Hardship 3Health News:What Stresses Teens Out 2Health News:What Stresses Teens Out 3
Liquichek Reticulocyte Control is a human whole blood based control designed to monitor manual and automated methods for counting reticulocytes. Assayed values are provided at three clinically signif...
Liquichek Hematology Control (C) is an assayed hematology control for evaluating the performance of Coulter hematology instruments with complete CBC and VCS 5-part differential technology....
... Liquichek Lipids Control is ... product that provides the ... analyte levels for lipids ... C-Reactive Protein in levels ...
... Control (Human) provides a comprehensive analyte ... and CO2. It requires no special ... major instruments and methodologies. Available in ... sizes (10 mL fill size available ...
Medicine Products: